Alopecia News and Research

RSS
Alopecia is the lack or loss of hair from areas of the body where hair is usually found. Alopecia can be a side effect of some cancer treatments.
Hedgehog blockade promising in myeloid malignancies

Hedgehog blockade promising in myeloid malignancies

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Cassiopea selects DATATRAK platform for significant global study

Cassiopea selects DATATRAK platform for significant global study

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Combined therapy boosts growth in short children with low IGF-1

Combined therapy boosts growth in short children with low IGF-1

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

FDA-approved drug eliminates immune cells that destroys hair follicles in people with alopecia areata

FDA-approved drug eliminates immune cells that destroys hair follicles in people with alopecia areata

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Arthritis drug promotes hair growth in hairless man

Arthritis drug promotes hair growth in hairless man

Shiseido Cell-Processing and Expansion Center to be opened in Kobe, Japan

Shiseido Cell-Processing and Expansion Center to be opened in Kobe, Japan

Protein that activates hair follicle growth inhibits fat production

Protein that activates hair follicle growth inhibits fat production

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Vaccine to treat precancerous cervical lesions triggers immune cell response

Vaccine to treat precancerous cervical lesions triggers immune cell response